Category: China
-
Novo Nordisk signs GLP-1 licensing agreement with China’s Hengrui Pharma
Novo Nordisk and Hengrui Pharma’s agreement, subject to antitrust approval, will allow Novo to obtain exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macao, and Taiwan.
-
Hong Kong’s pledge to become IP trading center is ‘game-changer’, but requires more than policy and financing platforms
Lawyers from both HK and China shared their thoughts on Hong Kong’s new Five-Year Plan, which pledges to transform it into a regional IP trading center. While they were generally positive, some were skeptical, highlighting that China’s own experience suggests government policy and trading platforms alone cannot create a liquid market for IP.
-
Daiichi Sankyo loses six CNIPA administrative patent-linkage cases over mirogabalin formulation patents
Daiichi Sankyo has now lost six Chinese patent-linkage cases over generic mirogabalin after the CNIPA found two dosage strengths outside three formulation patents. The rulings show the growing importance of CNIPA’s administrative route for resolving patent disputes before generic launch.
-
China’s top court reinforces human-inventor rule, scope of human-contribution standard likely to be tested in future litigation
China’s top court has reissued the rule that AI itself cannot be an inventor and expressly requires a natural person to make a creative contribution to an AI-assisted invention, bringing an approach already taken by the CNIPA into the judicial framework.
-
Nokia inks new patent licensing deals with Chinese TV makers
In a blog post today, the Head of Nokia’s Consumer Electronics licensing program, Philippe Lanet, said the agreements cover the use of Nokia’s technologies in their video-enabled devices.
-
China’s top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledge
A Chinese generic of Nefecon obtained formal approval after promising not to launch until patent expiry, then used that approval to seek procurement listings. China’s top court nevertheless held that the broken Paragraph III-style pledge was a regulatory breach – not an admission of patent infringement.
-
Align wins RMB 10M China injunction against Angelalign after UPC setback on related patent, parallel cases in injunction-tested Chinese venues
Align has won an injunction and RMB 10 million (approximately approximately $1.4 million) in damages against Angelalign in China, less than three months after the UPC refused provisional relief on a related European patent. The opposite outcomes add a new twist to their multi-jurisdictional patent fight.
-
China’s top court hands U.S. patentee landmark patent damages award
U.S. insecticide producer FMC Agriculture Singapore has been awarded a record of nearly 33 million Chinese yuan ($4.84 million) in patent infringement damages in a decision in which the defendant’s legal representative has also been found jointly liable – a rarity in Chinese IP infringement cases.
-
‘I am a latecomer’: former Xiaomi IP head Ran Xu on launching his own IP consultancy
Ran Xu talks to ip fray about where the idea to launch his consultancy, Rythan IP, came from, and why now was the ideal time to take the plunge.
-
China’s revised chip layout rules bring a patent-style revocation route, upfront identification of original features and punitive damages
China has created a patent-style CNIPA revocation route for chip layout-design disputes and introduced punitive damages of up to five times. The revised rules also require applicants to identify claimed original features and allow China to take countermeasures against discriminatory foreign restrictions on layout-design protection.